Van ECK Associates Corp lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 8.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 75,691 shares of the life sciences company’s stock after buying an additional 5,935 shares during the period. Van ECK Associates Corp owned about 0.05% of Illumina worth $35,818,000 at the end of the most recent reporting period.
Other institutional investors have also bought and sold shares of the company. Eagle Bay Advisors LLC bought a new stake in shares of Illumina in the 2nd quarter worth about $35,000. BDO Wealth Advisors LLC grew its holdings in Illumina by 90.5% during the 1st quarter. BDO Wealth Advisors LLC now owns 80 shares of the life sciences company’s stock valued at $31,000 after purchasing an additional 38 shares during the last quarter. Tsfg LLC grew its holdings in Illumina by 1,580.0% during the 2nd quarter. Tsfg LLC now owns 84 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 79 shares during the last quarter. Evoke Wealth LLC grew its holdings in Illumina by 165.6% during the 1st quarter. Evoke Wealth LLC now owns 85 shares of the life sciences company’s stock valued at $33,000 after purchasing an additional 53 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators bought a new position in Illumina during the 2nd quarter valued at about $43,000. Hedge funds and other institutional investors own 88.56% of the company’s stock.
ILMN has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $504.00 price target on the stock in a report on Wednesday, June 30th. Robert W. Baird reiterated a “hold” rating on shares of Illumina in a report on Sunday, August 22nd. Piper Sandler upped their price target on shares of Illumina from $510.00 to $560.00 and gave the company an “overweight” rating in a report on Friday, August 6th. Barclays upped their target price on shares of Illumina from $355.00 to $365.00 and gave the stock an “underweight” rating in a research note on Friday, August 6th. Finally, SVB Leerink downgraded shares of Illumina from an “outperform” rating to a “market perform” rating and set a $425.00 target price on the stock. in a research note on Thursday, August 19th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $392.06.
Shares of ILMN opened at $448.85 on Wednesday. The company has a 50 day moving average price of $482.60 and a 200-day moving average price of $438.65. Illumina, Inc. has a fifty-two week low of $260.42 and a fifty-two week high of $555.77. The stock has a market capitalization of $65.85 billion, a PE ratio of 85.99, a PEG ratio of 2.24 and a beta of 0.91. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.64 and a current ratio of 6.08.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, August 5th. The life sciences company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.51. Illumina had a net margin of 19.36% and a return on equity of 18.12%. The firm had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the prior year, the company earned $0.62 EPS. Equities research analysts forecast that Illumina, Inc. will post 6.48 EPS for the current year.
Illumina Company Profile
Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.
Further Reading: How do investors use RSI to grade stocks?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.